Hellenic Cooperative Oncology Group

This study looks back at tissue samples from patients with nasopharyngeal carcinoma who took part in an earlier treatment trial. Researchers are using advanced genetic testing and protein analysis to look for markers linked to how long patients survive. The goal is to better unde…

This study analyzes DNA and RNA from stored tumor samples of 401 people with head and neck squamous cell carcinoma. The goal is to classify each tumor by its genetic mutations and immune activity, potentially pointing toward which treatments—such as immunotherapy—might work best.…

This completed study looked at tumor samples from 687 women with advanced high-grade serous ovarian cancer who were treated with chemotherapy. Researchers examined different types of immune cells in the tumors to see if they were linked to how well patients did. The goal was to b…

This study looked at tissue samples from 2751 early breast cancer patients who had already completed chemotherapy. Researchers wanted to see if tumors with low levels of HER2 protein are biologically different from those with no HER2 at all. They used genetic testing and protein …

This completed study in Greece enrolled 200 people with stage 4 non-small cell lung cancer. Researchers used genetic testing to map each tumor's unique features and gave half the patients access to a digital platform to report side effects. The goal was to see if combining person…

This study examined tumor samples from 3,646 women with early-stage breast cancer who had already received chemotherapy after surgery. Researchers measured specific immune cells (tumor-infiltrating lymphocytes and CD8+ T cells) to see if their presence was linked to how long pati…

This study combined data from over 5,300 people with early-stage breast cancer who received a specific type of chemotherapy. Researchers wanted to see how long patients lived without the cancer coming back and what side effects they had. The goal is to learn from past treatments …

This completed study looked at 312 patients with advanced breast cancer who received either trastuzumab deruxtecan or sacituzumab govitecan. Researchers collected real-world information on side effects and how long the cancer was kept under control. The goal was to see how these …